drugset / Trial / NCT06954090
Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study
Phase 4
Enrolling by invitation
50 enrolled
Steno Diabetes Center Copenhagen
Mosaiques Diagnostics GmbH · collab
Non-randomizedParallel-groupOpen-labelOther
Summary
Title: Body fluid proteome SIGnatures for persoNALised intervention to prevent cardiovascular and renal complications in diabetes. Aim: To explore the feasibility of using urinary proteomic risk scores in clinical practice to identify patients at risk of developing end organ damage and identify which patients should receive additional renocardiovascular protective treatment.
Timeline
- Start
- 2025-11-20
- Primary completion
- 2026-11-30
- Completion
- 2027-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Dapagliflozin | Small molecule | 10 mg | — |
| Comparator | Finerenone | Small molecule | 10 mg | Oral |
| Comparator | Finerenone | Small molecule | 20 mg | Oral |
| Comparator | Semaglutide | Peptide | 1 mg | Subcutaneous |